Status:
COMPLETED
Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines
Lead Sponsor:
Allergan
Conditions:
Glabellar Rhytides
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
A study to evaluate safety and efficacy of treatment with botulinum toxin Type A (BOTOX®) in Chinese patients with moderate to severe frown lines (Glabellar Rhytides) previously treated with facial la...
Eligibility Criteria
Inclusion
- moderate or severe frown lines
- facial laser treatment between 4 to 8 weeks prior to Day 1
Exclusion
- previous use of botulinum toxin for any indication
- diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
- microdermabrasion or superficial peels, permanent make-up to the brow and forehead area within the last 3 months
- facial cosmetic procedures within the last 6 Months
- treatment to forehead, brow, nose or midface areas with any filler within the last 12 months
- use of a new topical skin care product within 1 month of the screening
- any prior forehead or periorbital surgery or brow lift
- deep dermal scarring, excessively thick sebaceous skin, and/ or loss of skin elasticity
- any facial skin infection or unhealed skin lesion
- pregnant or breast-feeding
Key Trial Info
Start Date :
March 6 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 29 2014
Estimated Enrollment :
185 Patients enrolled
Trial Details
Trial ID
NCT01814670
Start Date
March 6 2013
End Date
October 29 2014
Last Update
April 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, China